

Meta-analysis: do irritable bowel syndrome symptoms vary between men and women?

M. A. Adeyemo*, B. M. R. Spiegel† & L. Chang*

*Center for Neurobiology of Stress, Los Angeles, CA 90095, USA.

†VA Greater Los Angeles Healthcare System; Division of Digestive Diseases, David Geffen School of Medicine at UCLA; and UCLA/VA Center for Outcomes Research and Education (CORE), Los Angeles, CA 90073, USA.

Correspondence to:

Dr L. Chang, Center for the Neurobiology of Stress, CHS 47-122, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.
E-mail: linchang@ucla.edu

Publication data

Submitted 16 February 2010
First decision 5 March 2010
Resubmitted 23 June 2010
Accepted 23 June 2010

SUMMARY

Background

Studies suggest that sex and gender-related differences exist in irritable bowel syndrome (IBS), but data is often conflicting.

Aim

To evaluate gender differences and the effect of menstrual cycle and menopausal status on IBS symptoms.

Methods

We performed a systematic review of MEDLINE to search for studies comparing IBS symptoms between gender, menstrual cycle phases and menopausal states in IBS and/or healthy individuals. We performed meta-analyses to compare the relative risk (RR) of individual IBS symptoms between men and women.

Results

Twenty-two studies measured gender differences in IBS symptoms. Women were more likely to report abdominal pain (RR = 1.12, 95% CI: 1.02, 1.22) and constipation-related symptoms (RR = 1.12, 95% CI: 1.02, 1.23) than men (all $P < 0.05$). However, men with IBS were more likely to report diarrhoea-related symptoms than women with IBS (RR = 0.84, 95% CI: 0.75, 0.94, $P < 0.05$). A systematic review of 13 studies demonstrated that both IBS and healthy women reported increased IBS symptoms during menses vs. other phases. There were insufficient data to determine the effect of menopause and hormone supplementation on IBS symptoms.

Conclusions

In the general and IBS populations, gender differences in IBS symptoms exist, although these differences are modest. Studies suggest that female sex hormones influence the severity of IBS symptoms, but more studies are needed.

Aliment Pharmacol Ther

INTRODUCTION

Irritable bowel syndrome (IBS) is characterized by recurrent abdominal pain or discomfort associated with a change in bowel habits.¹ The prevalence of IBS ranges from 6% to 22% in Western countries, although the prevalence in Eastern countries tends to be lower and ranges from 2% to 17%.² IBS has a female predominance with a female-to-male ratio of 2–2.5:1 in those who seek health care. The female predominance is less apparent in the general population, which suggests that women with IBS are more likely to seek healthcare for their symptoms.^{3–7} However, some Asian studies fail to report significant gender differences in the prevalence of IBS, suggesting that cultural differences may also play a role in IBS symptom reporting.^{8, 9}

Gender differences in IBS are evident by subclassification, nongastrointestinal (GI) symptoms, pathophysiological responses and treatment response.¹⁰ Specifically, female predominance is particularly apparent in the IBS with constipation (IBS-C) subtype compared with IBS with diarrhoea (IBS-D) and alternating or mixed pattern (IBS-M).¹¹ Although gender differences in pathophysiological studies (e.g. GI transit, rectal perception, brain activation patterns) have been reported in IBS and healthy controls,^{12, 13} there are also conflicting reports that failed to identify differences between men and women.¹⁴ Response to some IBS treatments, such as serotonergic agents, appears to be more robust in women than in men.^{12, 15–17} However, these findings may be due to an inadequate number of men in IBS studies rather than a true gender difference in nonstudy populations. In fact, there have been inadequate efforts to enroll sufficient numbers of men in many IBS studies and inadequate attempts to control for menstrual cycle phase among women in these trials.¹⁰ In addition, gender differences and the effect of female sex hormones have largely been understudied in IBS. A recent review suggested that a strong relationship between menstrual cycle and bowel symptoms exists and that this may be due to effects of ovarian hormones on visceral pain sensitivity and bowel function.¹⁸

It is important to determine whether there are true symptom differences between genders in IBS because this information can potentially impact our understanding of the pathophysiology of IBS and influence research study design, drug development and treatment. Two previous reviews assessed gender differences in the *diagnosis* of IBS. One review was conducted in developing countries,¹⁹ whereas the other was a systematic review of

studies conducted in community populations.² Both reviews concluded that most Western studies supported a female predominance of IBS. However, approximately half of the studies conducted in Eastern countries reported a female predominance while the other half did not. Irrespective of whether the studies were conducted in Western or Eastern populations, the female-to-male ratio was dependent on the diagnostic criteria, i.e. a greater female predominance was seen when Manning criteria were used vs. Rome criteria.²

To understand better the gender differences in IBS, we performed a systematic review and meta-analysis of the literature to evaluate gender differences in *individual IBS symptoms* and the role of menstrual cycle, menopausal status and hormone supplementation on these symptoms. We hypothesized that the pooled data would reveal that women more frequently report abdominal pain and nonpain related symptoms associated with constipation such as hard stools, bloating, abdominal distension and straining than men, and that men more often report symptoms associated with diarrhoea such as loose stools and increased stool frequency. In addition, we hypothesized that the pooled data would reveal a higher prevalence of IBS symptoms at times when ovarian hormones are low, i.e. at the onset of menses in premenopausal women and during menopause, and that these symptoms decrease with hormone supplementation.

METHODS

Search strategy

The analysis for this study was based on a broader search for articles pertaining to dyspepsia and/or IBS. We conducted a comprehensive search for English language studies in MEDLINE published up to June 2010, which examined gender differences in IBS and/or the effect of menstrual cycle, menopausal status or hormone supplement on GI symptoms. The keywords and search strings used to perform the search with Reference Manager Software are indicated in Table 1. In addition, we performed manual searches of reference lists from relevant papers to identify other manuscripts, which may have been missed by the search strategy.

Screening strategy

We excluded titles if they did not meet the following inclusion criteria: (i) written in English; (ii) investigation of humans; (iii) examination of IBS or functional dyspepsia symptoms; (iv) assessment of IBS or functional

Table 1 Systematic review search strategy		
Group	Search terms	Significance of grouping
1	MEDLINE	Targeted bibliographic database
2	Irritable bowel syndrome [MeSH Terms] OR irritable bowel OR gastrointestinal transit [MeSH Terms] OR intestinal transit OR functional gastrointestinal disorder* OR gastrointestinal motility [MeSH Terms] OR visceral hyperalgesia OR functional colonic diseases OR colonic diseases OR gastrointestinal diseases OR gastrointestinal transit OR intestinal pseudo-obstruction OR dyspepsia Field: title/abstract	Targeted topic focus
3	Gender OR menstrual cycle [MeSH Terms] OR oestrogen* OR progesterone [MeSH Terms] OR menstruation [MeSH Terms] OR luteal phase [MeSH Terms] OR oral contraceptives [MeSH Terms] OR testosterone [MeSH Terms] OR sex characteristics [MeSH Terms] OR sex hormones OR gonadal steroid hormones OR estradiol congeners OR contraceptive agents OR contraceptives, oral, hormonal [MeSH Terms] OR contraceptives, oral, sequential [MeSH Terms] OR contraceptives, oral [MeSH Terms] OR menopause Field: text word	Targeted content keywords
4	Review OR letter OR news OR editorial Field: Publication Type NOT Cat OR mouse OR rat OR feline OR porcine OR canine OR dog OR bovine OR cow OR horse Field: text word	Excluded study types and content

MeSH, medical subject heading.

The four search groups were combined as follows: (1 AND 2 AND 3 NOT 4).

* Keyword truncation.

dyspepsia symptoms in relation to menstrual cycle, hormone supplement and/or gender; and (v) study population consisted of the general population, and/or patient with dyspepsia and/or IBS. The analysis for this study was based on a broader search for articles pertaining to IBS and/or dyspepsia. Two reviewers then independently assessed the relevancy of the abstracts for the remaining articles. We excluded abstracts that did not meet these criteria. Next, the two reviewers independently assessed the manuscripts of the remaining abstracts based on the prespecified inclusion criteria. Additionally, we manually reviewed the reference lists of identified studies to evaluate for extant literature not captured by the search strategy. In three cases, we contacted authors to obtain manuscripts. We applied Cohen's kappa statistic to assess inter-rater agreement and a third investigator resolved disagreements when necessary.

Data abstraction

We created a standardized data abstraction form to summarize information germane to the aims of this study.

We compiled and summarized abstracted data using pre-specified evidence tables.

Quality assessment

The Downs and Black (D&B) checklist was used to evaluate the quality of all studies (Appendix S1).²⁰ The D&B checklist was developed to assess the methodological quality of randomized and nonrandomized studies of health interventions. Of the few checklists available that assess the quality of both nonrandomized and randomized studies, the D&B checklist provides good test-retest reliability, inter-rater reliability and criterion validity. Several systematic reviews and meta-analyses have used modified versions of this checklist to assess study quality.^{21–23} The checklist is composed of 26 items subdivided into five components: reporting, internal validity, confounding, external validity and power. As 11 items in the original list were specific to randomized studies (intervention, randomization and power calculation), these items were not included in the assessment of quality of nonrandomized studies.

The maximum quality assessment (QA) score on the quality scales was 17 for nonrandomized studies and 32 for randomized studies. To compare the quality of the studies more effectively, we subjectively categorized the QA scores. For nonrandomized studies, the quality was rated as poor, intermediate and good if the QA score was 0–6, 7–11 and 12–17 respectively. For randomized studies, the quality was rated as poor, intermediate and good if the QA score was 0–10, 11–20 and 21–32 respectively.

Statistical analysis

We performed statistical analysis only on those studies investigating gender differences in IBS symptoms, and performed meta-analysis only for IBS symptoms that were assessed in ≥ 3 studies. We reported summary statistics as relative risk (RR) favouring women. All data were fitted into a 2×2 matrix to calculate the summary effect using the Mantel–Haenszel Method. In cases where none of the subjects reported a particular symptom, 1.0 was added to each cell of the 2×2 matrix.

We used Cochran's Q statistic to test for heterogeneity and adopted a P value of greater than 0.10 for the Q statistic as evidence for homogeneity.²⁴ If the data were homogeneous, we then selected a fixed-effects model.²⁴ If the data were heterogeneous, we then performed both a fixed and random-effects model.²⁴

We performed a qualitative appraisal of publication bias by constructing a funnel plot and observing for evidence of asymmetry,²⁴ and performed a quantitative appraisal for publication bias by conducting an Egger's test.²⁴ We assumed that there was evidence for publication bias if there was a qualitative lack of small 'negative' studies on the funnel plot, or if the P -value for the Egger's test was >0.10 .²⁴

All statistical analyses were conducted using STATA statistical software version 8.0 (Stata Corp. LP, College Station, TX, USA).

RESULTS

Of the 599 studies identified by the defined search strategy, 39 studies were included in our systematic review (Figure 1).^{9, 25–60} There was sufficient inter-rater agreement among the studies selected (abstract $\kappa = 0.73$ and content $\kappa = 0.83$ selection).⁶¹

Gender differences in IBS symptoms

Table 2 shows the general characteristics of the 22 studies (9 surveyed the general population sample, 12 studied




Figure 1 | Results of the literature search are shown.

an IBS only sample and 1 studied both general population and IBS) which compared prevalence rates of IBS symptoms in men and women.^{9, 25–36, 47, 51–54, 56, 58–60} Fourteen studies were considered of good quality and eight were considered of intermediate quality.

IBS diagnostic symptoms. In the general population, women were more likely to report abdominal pain and pain-related IBS diagnostic symptoms (Table 3, Figure 2).^{27–29, 31, 34–36, 51, 58} In contrast, in the IBS patient population, the prevalence of the pain-related symptoms did not differ between men and women.

Supportive symptoms. Overall, women were more likely to report supportive symptoms of IBS than men (Table 3). In the general population, gender differences were seen in predominantly constipation-related symptoms including abdominal distension, bloating and straining (Figure 2). The greatest gender disparities were seen with bloating and straining. Similarly, women with IBS demonstrated a considerably higher risk for constipation-related symptoms including abdominal distension, bloating, infrequent stools and hard stools than men with IBS (Figure 3). Men with IBS were significantly more likely to report the diarrhoea-related symptoms of loose/watery stools and increased stool frequency than women with IBS (Table 3).

Table 2 | Evidence table of studies comparing gender differences in IBS symptoms

Study	General population, N (% F)	IBS, N (% F)	Population	Study design	Setting	Country	IBS diagnostic criteria	QA
Bouchoucha <i>et al.</i> ²⁶	134 (42.5)	752 (74.2)	IBS and Controls	Cross-sectional	2° Care	France	Rome I and II	11
Kim and Ban ⁵¹	1717 (56.5)	N/A	General Population	Cross-sectional	University	Korea	N/A	15
Sandler <i>et al.</i> ⁵²	2510 (62.0)	N/A	General population	Cross-sectional	N/A	US	N/A	14
Shen <i>et al.</i> ⁵⁸	491 (50.9)	N/A	General population	Cross-sectional	University	China	N/A	8
Talley <i>et al.</i> ²⁷	835 (54.0)	N/A	General population	Cross-sectional	N/A	US	N/A	13
Talley <i>et al.</i> ²⁸	726 (53.7)	N/A	General population	Cross-sectional	N/A	Australia	N/A	13
Tan <i>et al.</i> ⁵³	533 (57.0)	N/A	General population	Cross-sectional	University	Malaysia	N/A	15
Taub <i>et al.</i> ²⁹	1344 (61.6)	N/A	General population	Cross-sectional	N/A	US	N/A	12
Tuteja <i>et al.</i> ³⁰	723 (60.7)	N/A	General population	Cross-sectional	N/A	US	N/A	15
Zuckerman <i>et al.</i> ³¹	405 (53.6)	N/A	General population	Cross-sectional	N/A	Vietnam	N/A	13
Celebi <i>et al.</i> ⁵⁴	N/A	111 (64.0)	IBS	Cross-sectional	1° Care	Turkey	Rome II	15
Barakzai <i>et al.</i> ⁴⁷	N/A	139 (71.4)	IBS	Retrospective	1° Care	US (Mexican-Americans)	Rome II criteria met in 58% of women and 79% men	11
Han <i>et al.</i> ⁹	N/A	70 (45.7)	IBS	Cross-sectional	Community	Korea	Rome II	15
Lee <i>et al.</i> ³²	N/A	714 (66.8)	IBS	Cross-sectional	Advertisement and 3° care	US	Rome	13
Lu <i>et al.</i> ³³	N/A	447 (40.5)	IBS	Cross-sectional	1° Care	China	Rome II	11
Masud <i>et al.</i> ²⁵	N/A	593 (61.3)	IBS	Cross-sectional	Community	Bangladesh	Rome	13
Perveen <i>et al.</i> ⁵⁶	N/A	116 (42.2)	IBS	Cross-sectional	Community	Bangladesh	Rome II	10
Ringel <i>et al.</i> ⁶⁰	N/A	337 (70.9)	IBS	Cross-sectional	Community	US	Modified Rome II	11
Schmulson <i>et al.</i> ⁵⁹	N/A	295 (67.8)	IBS	Cross-sectional	Advertisement and 2° care	Mexico	Rome II	11
Si <i>et al.</i> ³⁴	None	662 (52.9)	IBS	Cross-sectional	2° care	China	Rome II	15
Smith <i>et al.</i> ³⁵	None	97 (62.9)	IBS	Prospective	2° care	US	Modified Manning	9
Thompson ³⁶	None	156 (83.3)	IBS	Cross-sectional	1° and 2° care	US	90.4% met Manning criteria and 68.6% met Rome criteria	14

QA, quality assessment; N/A, not applicable; 1°, primary; 2°, secondary; 3°, tertiary.

Table 3 | Relative risk of IBS symptoms in women vs. men in both the general and IBS patient populations

	General population			IBS only		
	RR favouring women (95% CI)	No. studies	Heterogeneity (P)	RR favouring women (95% CI)	No. studies	Heterogeneity (P)
IBS diagnostic symptoms						
Pain	1.12 (1.02, 1.22)*	5	<0.001	N/A	1	
Pain relieved with defecation	1.13 (0.97, 1.31)	6	<0.001	1.00 (0.80, 1.25)	5	0.012
Pain associated with change in frequency	1.08 (1.03, 1.14)*	6	0.005	N/A	1	
Pain associated with change in form	1.12 (1.02, 1.23)*	6	<0.001	0.96 (0.82, 1.12)	4	0.69
Supportive symptoms						
Distension	N/A	2		1.29 (1.06, 1.56)*	5	0.002
Bloating	1.12 (1.01, 1.25)*	9	<0.001	1.37 (1.16, 1.61)*	6	0.028
Incomplete evacuation	1.03 (0.93, 1.13)	6	<0.001	1.15 (0.97, 1.37)	7	0.300
Infrequent stools	1.06 (0.99, 1.14)	5	<0.001	1.13 (1.08, 1.18)*	6	0.387
Lumpy/hard stools	0.98 (0.88, 1.10)	4	<0.001	1.21 (1.08, 1.36)*	5	0.089
Straining	1.12 (1.03, 1.23)*	4	<0.001	1.01 (0.93, 1.09)	5	0.284
Mucus	1.02 (0.97, 1.07)	5	<0.001	1.07 (0.96, 1.19)	8	0.002
Urgency	1.02 (0.93, 1.11)	4	<0.001	1.04 (0.95, 1.15)	6	0.249
Loose/watery stools	0.97 (0.92, 1.01)	5	0.002	0.84 (0.75, 0.94)*	5	0.420
Frequent stools	1.00 (0.98, 1.01)	4	0.635	0.88 (0.80, 0.96)*	5	0.014

RR, relative risk; CI, confidence interval; N/A, not applicable due to insufficient number of studies to perform meta-analysis.

* $P < 0.05$.




Figure 2 | Forest plots of the risk ratios and 95% confidence intervals for gender differences in general population studies evaluating abdominal pain, bloating and straining are shown.

Assessment for publication bias. Only two symptom comparisons surveyed in the general population showed a potential publication bias. Funnel plots suggest a lack of small, positive studies for abdominal pain associated with change in stool frequency and a lack of small, negative studies for frequent stools.

Menstrual cycle effect on IBS symptoms

Table 4 provides general information on the 13 studies that assessed the effect of menstrual cycle on IBS symptoms.^{32, 37-45, 62, 63} Study methodology varied with regard to study design and determination of menstrual cycle phase with seven studies of good quality and six of intermediate quality. Six studies assessed symptoms prospectively using daily diaries, two surveyed current symptom severity score and the remaining studies used symptom recall. Only two studies used ovulation kits to document menstrual cycle phase.

All but three studies stated that women (average 40–60%) reported increased GI symptoms at time of menses compared with other phases.^{32, 37-42, 44, 45, 62} The symptoms for which most studies showed a significant menstrual cycle effect were (in descending order) loose stools, bloating, abdominal pain, stool frequency and other changes in bowel habit (Figure 4, Table 4). In general, increased diarrhoea was reported at the time of menses by more women than increased constipation. Although menstrual cycle effects on symptoms were similar in healthy women and IBS women, symptom severity was greater in women with IBS.

If only the seven higher quality studies were assessed, five reported a menstrual cycle effect on IBS symptoms at time of menses, while two did not. Bloating, gas and bowel habit changes (diarrhoea more than constipation) were reported to increase at time of menses. Only three of these studies assessed symptoms prospectively and were from a single centre.




Figure 3 | Forest plots of the risk ratios and 95% confidence intervals for gender differences in IBS only studies evaluating bloating, distension, hard/lumpy stools and infrequent stools are shown.

Effect of menopausal status on IBS symptoms

Three retrospective and one prospective survey compared IBS symptoms in premenopausal vs. postmenopausal women^{32, 37, 46, 55} and were considered to be of high quality. Sample sizes for premenopausal women ranged from 58 to 89 subjects and postmenopausal women ranged from 55 to 170 subjects. Amongst the three studies restricted to IBS,^{32, 37, 55} nausea was the only symptom reported more frequently by premenopausal women than postmenopausal women.³² In the study by Cain *et al.*,⁵⁵ various GI symptoms were reported less frequently by premenopausal women than postmenopausal women; however, these differences were not significant after adjusting for age. Amongst healthy women, gaseousness and excessive flatulence were the only GI symptoms that were significantly more prevalent in postmenopausal women.

Effect of hormone supplementation on IBS symptoms

Table 5 shows the results from four studies which evaluated the effect of hormone supplementation on IBS

symptoms in pre- or postmenopausal women. Two of the studies were randomized controlled trials; one evaluating the effect of estradiol or progesterone in postmenopausal women⁵⁰ was of high quality and the other evaluating a gonadotropin-releasing hormone (GnRH) agonist in premenopausal women⁴⁹ was of intermediate quality. The other two studies were not randomized controlled trials. One consisted of a retrospective chart review⁴⁸ and the other was a prospective study,³⁹ but both achieved criteria for good quality.

Two studies investigated the effect of hormone replacement therapy (HRT) on IBS symptoms in women over the age of 50 who were presumably postmenopausal.^{48, 50} Ruigomez *et al.*⁴⁸ found that women who use HRT are more likely to develop IBS than women who do not; however, the prevalence and severity of IBS symptoms were similar among non-HRT users and HRT users. Gonne *et al.*⁵⁰ found that postmenopausal healthy women who were given estradiol or progesterone therapy alone for 7 days were more likely

Table 4 | Evidence table of studies comparing menstrual cycle effect on IBS symptoms

Study	Population (N)	Study design	Setting	Menstrual cycle assessment	IBS diagnostic criteria	Findings	QA
Jackson <i>et al.</i> ⁴¹	Healthy controls (20)	Prospective (daily diary)	Not specified	Menses: day 1-4; follicular: day 8-10; luteal: day 18-20; premenstrual: day 24-28	N/A	Stool form was significantly looser at menses compared to luteal phase; There was not a significant phase effect on number of stools per day	9
Hinds <i>et al.</i> ⁶²	Healthy controls (25)	Retrospective	Not specified	Recall	N/A	96% reported change in bowel habit before and during menses; 72% reported loose stools during menses; 32% reported constipation the week prior to menses	9
Simmons <i>et al.</i> ⁴⁴	Healthy controls (7)	Prospective (daily diary)	Not specified	Basal body temperature	N/A	No significant phase effect on stool form; 1 of 7 subjects reported constipation before or during menses; 2 of 7 subjects reported diarrhoea at the beginning of menses	11
Lee <i>et al.</i> ⁴³	GI clinic patients (193)	Cross-sectional (survey)	3° care	Menstrual: day 0-6; proliferative: day 7-14; secretory: after day 15	Rome II	50.8% of women met diagnostic criteria for IBS. No significant phase effect for abdominal pain, constipation, diarrhoea, abdominal distension, tenesmus	13
Altman <i>et al.</i> ⁶³	IBS (114)	Prospective (daily diary)	1° care and community	Menses: day 1; luteal phase: 7-10 days prior to onset of menses	Diagnosis made by health provider; criteria not specified	No significant phase effect on abdominal or stomach pain	13
Chang <i>et al.</i> ³⁷	IBS (380)	Retrospective	3° care and community	Recall	Rome I	40% of bloating patients and 43% of bloating + distension patients reported that bloating was related to menstrual cycle	15

Table 4 (Continued)							
Study	Population (N)	Study design	Setting	Menstrual cycle assessment	IBS diagnostic criteria	Findings	QA
Houghton et al. ⁴⁰	IBS (29)	Prospective (daily diary)	Not specified	Menses: day 1-4; follicular: day 8-10; luteal: day 18-20; premenstrual: day 24-28	Rome I	There were significant phase effects on abdominal pain, bloating, stool frequency and loose stools	11
Lee et al. ³²	IBS (477)	Retrospective	3° care and community	Recall	Rome	Overall 40% of women and 50.8% of women <45 years of age reported menstrual cycle-related worsening of symptoms	14
Heitkemper et al. ³⁸	IBS (149) Healthy controls (42)	Prospective (daily diary)	Community	Ovulation kit, counting days	Rome I	Severity of bloating and % days with loose stools (latter in IBS only) significantly increased during menses vs. other phases; no significant phase effect on abdominal pain, intestinal gas, constipation, diarrhoea or hard stools	16
Heitkemper et al. ³⁹	IBS (44) Healthy controls (25)	Prospective (daily diary)	Community	Ovulation kit	Rome	There was a significant phase effect on bloating and stool consistency; there was no phase effect on abdominal pain, intestinal gas or stool frequency	15

Table 4 | (Continued)

Study	Population (N)	Study design	Setting	Menstrual cycle assessment	IBS diagnostic criteria	Findings	QA
Houghton <i>et al.</i> ⁵⁷	IBS-D (39) Healthy controls (19)	Cross-sectional	University clinic, general practices, advertisement	Luteal phase (days 18-20 of cycle) or taking OCP were classified as high progesterone/oestrogen; menses (days 2-3) was classified as low progesterone/oestrogen: menses (days 2-3 of cycle)	Rome II	No differences in severity of pain, bloating, urgency or overall symptoms between high and low progesterone/oestrogen conditions in IBS-D women or healthy women	11
Kane <i>et al.</i> ⁴²	IBS (46) Healthy controls (90)	Retrospective	2° care and community	Recall	Rome	Increased diarrhoea was reported significantly more often during premenstrual period and menses in IBS vs. controls. Increased constipation was less often reported than diarrhoea, but was significantly more prevalent in IBS vs. controls during menses. There was a significant menstrual cycle effect on abdominal pain in IBS	16
Whitehead <i>et al.</i> ⁴⁵	IBS (72) Healthy controls (234)	Retrospective	1° and 2° care	Recall	Manning	IBS were more likely than controls to report menses-related increases in gas (39-48% vs. 14%), diarrhoea (29-32% vs. 19%) and constipation (18-24% vs. 11%)	11

QA, quality assessment; GI, gastrointestinal; N/A, not applicable; 1°, primary; 2°, secondary; 3°, tertiary; OCP, oral-contraceptive pills.




Figure 4 | The number of studies that tested for a significant effect of IBS symptoms on menstrual cycle is presented. The *P*-value of significance was specific to each study. One study was not included in the figure because statistical analysis of menstrual cycle effect on bloating was not performed.³⁷ Another study was not included because it did not specifically evaluate a menstrual cycle effect on these symptoms.⁴⁵

to have looser stools and greater ease of passage than those on placebo.

Two studies evaluated the effect of hormone supplementation on IBS symptoms in premenopausal women. One study assessed the effect of oral-contraceptive pills (OCP), whereas the other assessed the effect of a GnRH agonist.^{38, 49} Heitkemper *et al.*³⁸ found that OCP use by women with IBS was associated with lower abdominal pain severity compared with non-OCP users, but this difference did not maintain significance after correcting for multiple comparisons. Palomba *et al.*⁴⁹ found that treatment with a GnRH agonist improved the severity of IBS symptoms compared with placebo.

DISCUSSION

Due to conflicting data in the literature regarding gender differences in IBS, we performed a systematic review to investigate if there are differences in IBS symptoms between genders, and further evaluated the literature regarding the relationship between IBS symptoms, menstrual cycle phase and menopause. Our study has four main findings: (i) women experience a greater prevalence of IBS symptoms than men, particularly constipation-related symptoms; (ii) women appear to have more frequent and severe IBS symptoms during menses compared with other phases of the menstrual cycle; (iii) the effect of hormonal therapy on IBS symptoms cannot be determined based on limited available data; and (iv)

there is a lack of studies comparing IBS symptoms in pre- and postmenopausal women.

For the most part, the occurrence and diagnosis of IBS is more common in women than in men.^{6, 29, 64} Female gender is a significant independent risk factor for the development of IBS,⁶⁵ including postinfectious IBS.⁶⁶ In cross-sectional surveys conducted in the US,⁶⁷ Canada⁶⁸ and Israel,⁶⁹ women reported IBS symptoms 1.5 to 2 times more commonly than men. Greater health care seeking and referral for IBS in women may in part be due to increased IBS severity^{32, 70, 71} and greater impact of symptoms on health related quality of life in women with IBS compared with men.^{70, 72, 73} However, population studies conducted in Asia suggest that the prevalence of IBS in men and women is similar.^{19, 74–76} This difference may be largely due to cultural reasons. In Asia, men see physicians as much and more often than women possibly for cultural and economic reasons.^{76–79}

Gender differences in IBS symptoms

Our meta-analysis reveals that women more frequently report individual IBS symptoms than men. In general population studies, which included individuals with IBS, women reported a greater prevalence of the IBS diagnostic (i.e. pain-related) symptoms than men. These findings are consistent with studies which showed an enhanced perception of pain or discomfort to distension in the colon and rectum in women vs. men.^{80, 81}

Overall, women had a greater prevalence of constipation-associated symptoms, particularly bloating and abdominal distension, than men. Men had a greater prevalence of diarrhoea-associated symptoms of loose/watery stools and increased stool frequency in the IBS only studies, but not in the general population studies. This is consistent with studies demonstrating a female predominance in IBS-C^{67, 82, 83} and chronic constipation.^{82, 84} Several studies have found that women have slower colonic transit than men.^{85–87}

The generally higher IBS symptom reporting in women than men may be due to several reasons. Since women with IBS tend to have significantly more healthcare visits than men,⁸⁸ studies which used healthcare-based recruitment methods may underestimate the symptom prevalence in men. Another plausible explanation is that women tend to recall their symptoms better than men.⁸⁹ However, this is not likely to explain why constipation-associated symptoms were reported more commonly in women than in men, while diarrhoea-associated symptoms were reported more often in men. Gender differences have been demonstrated in GI function, including

Table 5 | Evidence table of studies comparing hormone supplement effect on IBS

Study	Treatment groups (N)	Population	Menopausal status	Study design	Age (years)	Setting	IBS diagnostic criteria	Symptoms	QA
Ruigomez <i>et al.</i> ⁴⁸	IBS HRT users (405); IBS HRT never users (255)	IBS	Not specified	Prospective	50-69	1° care	Not specified	IBS symptoms were similar among users of HRT and HRT never users (data not provided)	15
Palomba <i>et al.</i> ⁴⁹	Leuprolide acetate depot (LAD) plus tibolone (36); LAD plus placebo (37); placebo (39)	IBS	Premenopausal	RCT	25.5 (mean)	2° care	Rome II	There was an improvement from baseline and vs. placebo in abdominal discomfort and distension, nausea, frequency and consistency, diarrhoea, constipation and bloating for both treatment groups	17
Gonenne <i>et al.</i> ⁵⁰	Placebo (12), progesterone (13), estradiol (12), combined progesterone and estradiol (12)	Controls	Postmenopausal	RCT	40-65	Not specified	N/A	Treatment effect of looser stool consistency scores with progesterone alone, estradiol alone and progesterone + estradiol; Greater ease of passage scores for estradiol alone; No treatment effect on stool frequency, stool consistency or sense of incomplete passage	24
Heitkemper <i>et al.</i> ³⁸	IBS oral contraceptive (56); IBS non-OCP (93)	IBS	Premenopausal	Prospective	32.5 (mean)	General population	Rome I	OCP users reported less severe abdominal pain than non-OCP users but this difference did not maintain significance after multiple comparisons. There were no significant differences in other individual GI symptoms	16

RCT, randomized controlled trial; 1°, primary; 2°, secondary; 3°, tertiary; HRT, hormone replacement therapy; OCP, oral-contraceptive pills; N/A, not applicable.

transit time, visceral perception, brain activation patterns and colonic mucosal mast cell count^{12, 13, 81, 90, 91} which can conceivably contribute to the greater prevalence of IBS symptoms in women and the gender differences in bowel habits.

Most Western studies reported a higher prevalence of individual IBS symptoms in women compared with men.^{26, 27, 29, 30, 35, 36} Similarly, eight of the ten Eastern studies found that more women reported individual IBS symptoms than men^{9, 31, 33, 34, 51, 53, 56, 58}; however one of these studies also reported higher prevalences of loose stools and increased stool frequency in men.³³ These studies were conducted mainly in community and university clinic populations, although one surveyed secondary clinic patients. Interestingly, two studies did not find a gender difference in individual symptoms, but reported a higher ratio of women-to-men with Rome positive IBS (1.3–1.8:1).^{25, 54} One of these studies was conducted in a rural community in Bangladesh²⁵ and the other in an urban community in Turkey.⁵⁴ Thus, this meta-analysis supports a higher overall prevalence of IBS symptoms in women than in men in Western and Eastern countries, although the differences are relatively modest. This review overcomes the limitations of previous epidemiological investigations^{9, 26–28, 30–36, 47} because data from studies conducted in both Eastern and Western populations are included. However, additional studies are needed to investigate how the interactions between genetic, environmental and/or cultural factors contribute to gender differences in IBS symptoms and may differ across diverse cultures.

The relatively small, but significant gender differences in the prevalence of individual IBS symptoms suggests that gender effects may be confounded by other factors that significantly influence the presence of IBS symptoms. These include psychological and social factors that can affect symptom reporting, health care seeking and global outcomes in IBS.⁹² For example, studies have reported that a previous history of abuse and other traumatic events or stressors are associated with more severe pain and greater symptom severity in IBS.^{93–96}

Limitations of our meta-analysis include the extensive heterogeneity of the studies, which may in part explain the low RR estimates. For example, the diagnostic criteria used for IBS varied between studies. This is notable because gender differences in the prevalence of IBS vary according to criteria used.⁹⁷ In a population-based, cross-sectional survey study in Olmstead County, Minnesota, there was a greater prevalence of women with IBS if the Manning criteria were used, but a higher prevalence of men with IBS if the Rome criteria were used.⁹⁸

Menstrual cycle effect on IBS symptoms

Our systematic review found that IBS symptoms are heightened at time of menses. Enhanced visceral perception at menses is supported by the finding of decreased sensory thresholds to rectal distension compared with other phases of the menstrual cycle.⁴⁰ One plausible mechanism that is supported by some animal and human studies is that declining or low ovarian hormone levels at time of menses may underlie the increased GI symptoms and discomfort across the menstrual cycle.⁹⁹ A study by Laessle and colleagues¹⁰⁰ showed that progesterone levels negatively correlated with pain-related symptoms (i.e. back pain and headache) which supports that lower levels of female sex hormones are associated with greater somatic pain. It is conceivable that women have more prevalent and severe IBS symptoms at time of menses when progesterone (and oestrogen) decline from high to low levels. There are other possible mechanisms involved in GI function to explain these findings. For example, gender differences exist in postprandial serotonin levels in IBS-D^{101, 102} and in colonic mucosal mast cell counts in IBS.⁹¹ Both have been found to correlate with IBS symptoms and potentially have a key role in the pathophysiology of IBS.¹⁰³ In addition, mast cell secretion is affected by both oestrogen and progesterone.¹⁰⁴

Although more studies reported increased diarrhoea at time of menses than increased constipation, there were two retrospective recall studies which found that some women reported increased diarrhoea and others reported increased constipation (Table 4).^{42, 45} It is possible that an increase in a particular bowel habit would be reported by IBS patients with that predominant bowel subtype. For example, women with IBS-D may be more likely to report increased diarrhoea than constipation, while IBS-C patients may be more likely to report increased constipation. However, this information was not available in the studies to determine if this could explain these findings.

Despite a relatively adequate number of studies, methodological limitations in these studies could have affected the results. Half of the studies were based on symptom recall. As women are likely to report a greater severity of symptoms retrospectively than prospectively,¹⁰⁵ the retrospective studies may overestimate the effect of menstrual cycle on IBS symptoms and are less accurate than prospective assessment. In addition, confirmation of menstrual cycle phase should be performed using ovulation kits, although this was only done in two of the 12 studies. A review of the effect of menstrual cycle phase on experimental pain response found a lack of standard-

ized operational definitions for identifying menstrual cycle phases.¹⁰⁶ More studies with an optimal study design (e.g. use of ovulation kits, prospective daily symptom assessment, sufficient sample sizes) are needed to truly assess the validity of the menstrual cycle effect on IBS symptoms.

Menopausal status effect on IBS symptoms

Due to the small number of studies that compared GI symptoms in pre- and postmenopausal women, there is insufficient evidence to determine the effect of menopausal status on IBS symptoms. However, the limited data suggest that premenopausal women with IBS are more likely to experience nausea than postmenopausal women with IBS. This finding is supported by studies which have shown that nausea and vomiting that occurred post-operatively,^{107, 108} and during pregnancy,^{109, 110} are associated with high levels oestrogen and/or progesterone levels.

In one study, healthy postmenopausal women reported gas and excessive flatulence significantly more than premenopausal women.⁴⁶ To our knowledge, there have been no studies that have compared intestinal gas clearance or colon transit times in pre- and postmenopausal women.

Effect of hormone supplement on IBS symptoms

The available studies provided limited information and therefore a conclusion on the effects of hormone supplementation cannot be definitively determined. However, the available evidence suggests that use of OCPs and a GnRH agonist by premenopausal women may be protective of IBS symptoms, although further studies are needed. These medications act differently on the hypothalamic–pituitary–gonadal axis. OCPs prevent ovulation because the progesterone derivative inhibits the release of GnRH by the hypothalamus thereby decreasing the release of follicular-stimulating hormone (FSH) and luteinizing hormone (LH) by the anterior pituitary, and oestrogen inhibits follicular development. In contrast, leuprolide, the GnRH agonist, stimulates the release of FSH and LH, which suppress the secretion of ovarian hormones. Undoubtedly, more studies are needed to determine conclusively the effect of hormone supplements on IBS symptoms.

CONCLUSION

Our study demonstrates that women overall have a greater prevalence of IBS symptoms than men, particu-

larly those associated with constipation. However, within the IBS patient group, men have more diarrhoea symptoms than women. There are some limitations in the quality, methodology and number of studies evaluating the effect of menstrual cycle, hormone supplementation and menopausal status on IBS symptoms. Notably, most studies relied on symptom recall. Nonetheless, existing data raise the possibility that there may be a female sex hormone effect on IBS symptoms as well as on GI function. It is plausible that this may contribute to the increased prevalence and greater vulnerability to develop IBS, the higher prevalence of constipation symptoms and the increased severity of symptoms at time of menses in women. In addition to the need for more, well-designed studies, there should be a greater attempt to recruit adequate and comparable numbers of men and women with and without IBS, and attention should be paid to assessing and controlling for menstrual cycle phase and menopausal status in clinical study design as they can potentially affect study results.

ACKNOWLEDGEMENTS

Declaration of personal interests: The authors thank Melissa Alberto and Teresa Olivas for their assistance in the preparation of the work. Mopelola Adeyemo has nothing to declare. Brennan Spiegel has served as a consultant for Prometheus Laboratories, Astra-Zeneca, TAP, Takeda, Ironwood, and Novartis. He has received research funding from Takeda, Rose, Prometheus, Amgen, Shire, and Novartis. Lin Chang has served as a consultant for Prometheus Laboratories, Takeda, Forest, Albireo, McNeil, Rose Pharma, Glaxo-SmithKline, Salix, Ocera and Movetis. She has received research funding from Takeda, Rose and Prometheus. *Declaration of funding interests:* This study was funded by NIH Grants Nos P50 DK64539 and R24 AT002681.

SUPPORTING INFORMATION

Additional Supporting Information may be found in the online version of this article:

Appendix S1. Down and Black checklist for measuring study quality.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

REFERENCES

- Drossman DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology* 2006; **130**: 1377–90.
- Kang JY. Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. *Aliment Pharmacol Ther* 2005; **21**: 663–76.
- Camilleri M, Choi MG. Review article: irritable bowel syndrome. *Aliment Pharmacol Ther* 1997; **11**: 3–15.
- Talley NJ. Irritable bowel syndrome: definition, diagnosis and epidemiology. *Baillieres Best Pract Res Clin Gastroenterol* 1999; **13**: 371–84.
- Thompson DG. GLP-1 and the gut. *Gut* 2000; **46**: 591.
- Muller-Lissner SA, Bollani S, Brummer RJ, et al. Epidemiological aspects of irritable bowel syndrome in Europe and North America. *Digestion* 2001; **64**: 200–4.
- Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. *Gastroenterology* 2002; **123**: 2108–31.
- Husain N, Chaudhry IB, Jafri F, Niaz SK, Tomenson B, Creed F. A population-based study of irritable bowel syndrome in a non-Western population. *Neurogastroenterol Motil* 2008; **20**: 1022–9.
- Han SH, Lee OY, Bae SC, et al. Prevalence of irritable bowel syndrome in Korea: population-based survey using the Rome II criteria. *J Gastroenterol Hepatol* 2006; **21**: 1687–92.
- Chang L, Heitkemper MM. Gender differences in irritable bowel syndrome. *Gastroenterology* 2002; **123**: 1686–701.
- Talley NJ, Zinsmeister AR, Melton III LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. *Am J Epidemiol* 1995; **142**: 76–83.
- Viramontes BE, Camilleri M, McKinzie S, Pardi DS, Burton D, Thomforde GM. Gender-related differences in slowing colonic transit by a 5-HT₃ antagonist in subjects with diarrhea-predominant irritable bowel syndrome. *Am J Gastroenterol* 2001; **96**: 2671–9.
- Rao SS, Sadeghi P, Beaty J, Kavlock R, Ackerson K. Ambulatory 24-h colonic manometry in healthy humans. *Am J Physiol Gastrointest Liver Physiol* 2001; **280**: G629–39.
- Soffer EE, Kongara K, Achkar JP, Gannon J. Colonic motor function in humans is not affected by gender. *Dig Dis Sci* 2000; **45**: 1281–4.
- Drossman DA, Chey W, Panas R, Wahle A, Scott C, Ueno R. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two twelve week, randomized, placebo controlled double blind trials. *Gastroenterology* 2007; **132**: 2586–7.
- Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. *Am J Gastroenterol* 2005; **100**: 115–23.
- Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. *Clin Gastroenterol Hepatol* 2008; **6**: 545–55.
- Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? *Gend Med* 2009; **6**(Suppl 2): 152–67.
- Gwee KA. Irritable bowel syndrome in developing countries – a disorder of civilization or colonization? *Neurogastroenterol Motil* 2005; **17**: 317–24.
- Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health* 1998; **52**: 377–84.
- McMillan AM, Landorf KB, Barrett JT, Menz HB, Bird AR. Diagnostic imaging for chronic plantar heel pain: a systematic review and meta-analysis. *J Foot Ankle Res* 2009; **2**: 32.
- Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. *BMJ* 2009; **339**: b4567.
- Tonelli M, Wiebe N, Hemmelgarn B, et al. Trace elements in hemodialysis patients: a systematic review and meta-analysis. *BMC Med* 2009; **7**: 25.
- Egger M, Altman DG, Smith GD, eds. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: *BMJ Publish Group*, 2001.
- Masud MA, Hasan M, Khan AK. Irritable bowel syndrome in a rural community in Bangladesh: prevalence, symptoms pattern, and health care seeking behavior. *Am J Gastroenterol* 2001; **96**: 1547–52.
- Bouchoucha M, Devroede G, Dorval E, Faye A, Arhan P, Arzac M. Different segmental transit times in patients with irritable bowel syndrome and “normal” colonic transit time: is there a correlation with symptoms? *Tech Coloproctol* 2006; **10**: 287–96.
- Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ. Epidemiology of colonic symptoms and irritable bowel syndrome. *Gastroenterology* 1991; **101**: 927–34.
- Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. *Gut* 1998; **42**: 690–5.
- Taub E, Cuevas JL, Cook EW, Crowell M, Whitehead WE. Irritable bowel syndrome defined by factor analysis. Gender and race comparisons. *Dig Dis Sci* 1995; **40**: 2647–55.
- Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. *Am J Gastroenterol* 2008; **103**: 1241–8.
- Zuckerman MJ, Nguyen G, Ho H, Nguyen L, Gregory GG. A survey of irritable bowel syndrome in Vietnam using the Rome criteria. *Dig Dis Sci* 2006; **51**: 946–51.
- Lee OY, Mayer EA, Schmulson M, Chang L, Naliboff B. Gender-related differences in IBS symptoms. *Am J Gastroenterol* 2001; **96**: 2184–93.
- Lu CL, Chang FY, Lang HC, Chen CY, Luo JC, Lee SD. Gender difference on the symptoms, health-seeking behaviour, social impact and sleep quality in irritable bowel syndrome: a Rome II-based survey in an apparent healthy adult Chinese population in Taiwan. *Aliment Pharmacol Ther* 2005; **21**: 1497–505.
- Si JM, Wang LJ, Chen SJ, Sun LM, Dai N. Irritable bowel syndrome consulters in Zhejiang province: the symptoms pattern, predominant bowel habit subgroups and quality of life. *World J Gastroenterol* 2004; **10**: 1059–64.
- Smith RC, Greenbaum DS, Vancouver JB, et al. Gender differences in Manning criteria in the irritable bowel syndrome. *Gastroenterology* 1991; **100**: 591–5.
- Thompson WG. Gender differences in irritable bowel syndromes. *Eur J Gastroenterol Hepatol* 1997; **9**: 299–302.

37. Chang L, Lee OY, Naliboff B, Schmulson M, Mayer EA. Sensation of bloating and visible abdominal distension in patients with irritable bowel syndrome. *Am J Gastroenterol* 2001; **96**: 3341–7.
38. Heitkemper MM, Cain KC, Jarrett ME, Burr RL, Hertig V, Bond EF. Symptoms across the menstrual cycle in women with irritable bowel syndrome. *Am J Gastroenterol* 2003; **98**: 420–30.
39. Heitkemper MM, Jarrett M, Cain KC, Shaver J, Walker E, Lewis L. Daily gastrointestinal symptoms in women with and without a diagnosis of IBS. *Dig Dis Sci* 1995; **40**: 1511–9.
40. Houghton LA, Lea R, Jackson N, Whorwell PJ. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. *Gut* 2002; **50**: 471–4.
41. Jackson NA, Houghton LA, Whorwell PJ, Currer B. Does the menstrual cycle affect anorectal physiology? *Dig Dis Sci* 1994; **39**: 2607–11.
42. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. *Am J Gastroenterol* 1998; **93**: 1867–72.
43. Lee SY, Kim JH, Sung IK, et al. Irritable bowel syndrome is more common in women regardless of the menstrual phase: a Rome II-based survey. *J Korean Med Sci* 2007; **22**: 851–4.
44. Simmons L, Heitkemper M, Shaver J. Gastrointestinal function during the menstrual cycle. *Health Care Women Int* 1988; **9**: 201–9.
45. Whitehead WE, Cheskin LJ, Heller BR, et al. Evidence for exacerbation of irritable bowel syndrome during menses. *Gastroenterology* 1990; **98**: 1485–9.
46. Triadafilopoulos G, Finlayson M, Grellet C. Bowel dysfunction in postmenopausal women. *Women Health* 1998; **27**: 55–66.
47. Barakzai MD, Gregory J, Fraser D. The effect of culture on symptom reporting: Hispanics and irritable bowel syndrome. *J Am Acad Nurse Pract* 2007; **19**: 261–7.
48. Ruigomez A, Garcia Rodriguez LA, Johansson S, Wallander MA. Is hormone replacement therapy associated with an increased risk of irritable bowel syndrome? *Maturitas* 2003; **44**: 133–40.
49. Palomba S, Orio F Jr., Manguso F, et al. Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome. *Fertil Steril* 2005; **83**: 1012–20.
50. Gonne J, Esfandyari T, Camilleri M, et al. Effect of female sex hormone supplementation and withdrawal on gastrointestinal and colonic transit in postmenopausal women. *Neurogastroenterol Motil* 2006; **18**: 911–8.
51. Kim YJ, Ban DJ. Prevalence of irritable bowel syndrome, influence of lifestyle factors and bowel habits in Korean college students. *Int J Nurs Stud* 2005; **42**: 247–54.
52. Sandler RS, Stewart WF, Liberman JN, Ricci JA, Zorich NL. Abdominal pain, bloating, and diarrhea in the United States: prevalence and impact. *Dig Dis Sci* 2000; **45**: 1166–71.
53. Tan YM, Goh KL, Muhidayah R, Ooi CL, Salem O. Prevalence of irritable bowel syndrome in young adult Malaysians: a survey among medical students. *J Gastroenterol Hepatol* 2003; **18**: 1412–6.
54. Celebi S, Acik Y, Devenci SE, et al. Epidemiological features of irritable bowel syndrome in a Turkish urban society. *J Gastroenterol Hepatol* 2004; **19**: 738–43.
55. Cain KC, Jarrett ME, Burr RL, Rosen S, Hertig VL, Heitkemper MM. Gender differences in gastrointestinal, psychological, and somatic symptoms in irritable bowel syndrome. *Dig Dis Sci* 2009; **54**: 1542–9.
56. Perveen I, Hasan M, Masud MA, Bhuiyan MM, Rahman MM. Irritable bowel syndrome in a Bangladeshi urban community: prevalence and health care seeking pattern. *Saudi J Gastroenterol* 2009; **15**: 239–43.
57. Houghton LA, Brown H, Atkinson W, et al. 5-hydroxytryptamine signalling in irritable bowel syndrome with diarrhoea: effects of gender and menstrual status. *Aliment Pharmacol Ther* 2009; **30**: 919–29.
58. Shen L, Kong H, Hou X. Prevalence of irritable bowel syndrome and its relationship with psychological stress status in Chinese university students. *J Gastroenterol Hepatol* 2009; **24**: 1885–90.
59. Schmulson M, Adeyemo M, Gutierrez-Reyes G, et al. Differences in gastrointestinal symptoms according to gender in Rome II positive IBS and dyspepsia in a Latin American population. *Am J Gastroenterol* 2010; **105**: 925–32.
60. Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. *Clin Gastroenterol Hepatol* 2009; **7**: 68–72.
61. Landis JR, Koch GG. A review of statistical methods in the analysis of data arising from observer reliability studies, Parts I and II. *Stat Neerl* 1975; **29**: 101–23.
62. Hinds JP, Stoney B, Wald A. Does gender or the menstrual cycle affect colonic transit? *Am J Gastroenterol* 1989; **84**: 123–6.
63. Altman G, Cain KC, Motzer S, Jarrett M, Burr R, Heitkemper M. Increased symptoms in female IBS patients with dysmenorrhea and PMS. *Gastroenterol Nurs* 2006; **29**: 4–11.
64. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. *Aliment Pharmacol Ther* 2005; **21**: 1365–75.
65. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. *Am J Gastroenterol* 2007; **102**: 1–11.
66. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. *BMJ* 1997; **314**: 779–82.
67. Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. *Aliment Pharmacol Ther* 2005; **22**: 935–42.
68. Thompson WG, Irvine EJ, Pare P, Ferrazzi S, Rance L. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. *Dig Dis Sci* 2002; **47**: 225–35.
69. Sperber AD, Friger M, Shvartzman P, et al. Rates of functional bowel disorders among Israeli Bedouins in rural areas compared with those who moved to permanent towns. *Clin Gastroenterol Hepatol* 2005; **3**: 342–8.
70. Coffin B, Dapoigny M, Cloarec D, Comet D, Dyard F. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome. *Gastroenterol Clin Biol* 2004; **28**: 11–5.
71. Van der Horst VG, Holstege G. Sensory and motor components of reproductive behavior: pathways and plasticity. *Behav Brain Res* 1998; **92**: 157–67.
72. van der Horst HE, van Dulmen AM, Schellevis FG, van Eijk JT, Fennis JF, Bleijenberg G. Do patients with irritable bowel syndrome in primary care really differ from outpatients with irritable bowel syndrome? *Gut* 1997; **41**: 669–74.
73. Simren M, Abrahamsson H, Svedlund J, Bjornsson ES. Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. *Scand J Gastroenterol* 2001; **36**: 545–52.

74. Gwee KA, Wee S, Wong ML, Png DJ. The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an Asian urban community. *Am J Gastroenterol* 2004; **99**: 924–31.
75. Xiong LS, Chen MH, Chen HX, Xu AG, Wang WA, Hu PJ. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling. *Aliment Pharmacol Ther* 2004; **19**: 1217–24.
76. Lu CL, Chen CY, Lang HC, *et al.* Current patterns of irritable bowel syndrome in Taiwan: The Rome II questionnaire on a Chinese population. *Aliment Pharmacol Ther* 2003; **17**: 217–24.
77. Drossman DA, Weinland SR. Commentary: sociocultural factors in medicine and gastrointestinal research. *Eur J Gastroenterol Hepatol* 2008; **20**: 593–5.
78. Jain AP, Gupta OP, Jajoo UN, Sidhwa HK. Clinical profile of irritable bowel syndrome at a rural based teaching hospital in central India. *J Assoc Physicians India* 1991; **39**: 385–6.
79. Pimparkar BD. Irritable colon syndrome. *J Indian Med Assoc* 1970; **54**: 95–103.
80. Ragnarsson G, Hallbook O, Bodemar G. Abdominal symptoms are not related to anorectal function in the irritable bowel syndrome. *Scand J Gastroenterol* 1999; **34**: 250–8.
81. Chang L, Naliboff BD, Labus JS, *et al.* Effect of sex on perception of rectosigmoid stimuli in irritable bowel syndrome. *Am J Physiol Regul Integr Comp Physiol* 2006; **291**: R277–84.
82. Jun DW, Park HY, Lee OY, *et al.* A population-based study on bowel habits in a Korean community: prevalence of functional constipation and self-reported constipation. *Dig Dis Sci* 2006; **51**: 1471–7.
83. Katsinelos P, Lazaraki G, Kountouras J, *et al.* Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece. *Eur J Gastroenterol Hepatol* 2009; **21**: 183–9.
84. Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. *Am J Gastroenterol* 2001; **96**: 3130–7.
85. Metcalf AM, Phillips SF, Zinsmeister AR, MacCarty RL, Beart RW, Wolff BG. Simplified assessment of segmental colonic transit. *Gastroenterology* 1987; **92**: 40–7.
86. Meier R, Beglinger C, Dederding JP, *et al.* Influence of age, gender, hormonal status and smoking habits on colonic transit time. *Neurogastroenterol Motil* 1995; **7**: 235–8.
87. Lampe JW, Fredstrom SB, Slavin JC, Potter JD. Sex differences in colonic function: a randomised trial. *Gut* 1993; **34**: 531–6.
88. Shih YC, Barghout VE, Sandler RS, *et al.* Resource utilization associated with irritable bowel syndrome in the United States 1987–1997. *Dig Dis Sci* 2002; **47**: 1705–15.
89. Jonsson B, Gardsell P, Johnell O, Redlund-Johnell I, Sernbo I. Remembering fractures: fracture registration and proband recall in southern Sweden. *J Epidemiol Community Health* 1994; **48**: 489–90.
90. Naliboff BD, Berman S, Chang L, Derbyshire SWG, Suyenobu B, Vogt BA, Mandelkern MA, Mayer EA. Sex-related differences in IBS patients: central processing of visceral stimuli. *Gastroenterology* 2003; **124**: 1738–47.
91. Cremon C, Gargano L, Morselli-Labate AM, *et al.* Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. *Am J Gastroenterol* 2009; **104**: 392–400.
92. Levy RL, Olden KW, Naliboff BD, *et al.* Psychosocial aspects of the functional gastrointestinal disorders. *Gastroenterology* 2006; **130**: 1447–58.
93. Drossman DA, Talley NJ, Leserman J, Olden KW, Barreiro MA. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. *Ann Intern Med* 1995; **123**: 782–94.
94. Drossman DA, Li Z, Leserman J, Toomey TC, Hu YJ. Health status by gastrointestinal diagnosis and abuse history. *Gastroenterology* 1996; **110**: 999–1007.
95. Drossman DA, Leserman J, Li Z, Keefe F, Hu YJ, Toomey TC. Effects of coping on health outcome among women with gastrointestinal disorders. *Psychosom Med* 2000; **62**: 309–17.
96. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. *Am J Gastroenterol* 2001; **96**: 1340–9.
97. Sperber AD, Shvartzman P, Friger M, Fich A. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the ‘true’ prevalence of irritable bowel syndrome? *Eur J Gastroenterol Hepatol* 2007; **19**: 441–7.
98. Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ 3rd. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. *Am J Gastroenterol* 2000; **95**: 2816–24.
99. Heitkemper M, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? *Gend Med* 2009; **6**: 152–67.
100. Laessle RG, Tuschl RJ, Schweiger U, Pirke KM. Mood changes and physical complaints during the normal menstrual cycle in healthy young women. *Psychoneuroendocrinology* 1990; **15**: 131–8.
101. Li TJ, Yu BP, Dong WG, Luo HS, Xu L, Li MQ. Ovarian hormone modulates 5-hydroxytryptamine 3 receptors mRNA expression in rat colon with restraint stress-induced bowel dysfunction. *World J Gastroenterol* 2004; **10**: 2723–6.
102. Houghton LA, Perry H, Morris J, Whorwell PJ, Keevil B. Plasma 5-hydroxytryptamine concentration varies with gender and menstrual status in irritable bowel syndrome patients with diarrhoea (IBS-D) but not healthy volunteers. *Gastroenterology* 2008; **134**: A-681.
103. Barbara G, Stanghellini V, De Giorgio R, *et al.* Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology* 2004; **126**: 693–702.
104. Vasiadi M, Kempuraj D, Boucher W, Kalogeromitos D, Theoharides TC. Progesterone inhibits mast cell secretion. *Int J Immunopathol Pharmacol* 2006; **19**: 787–94.
105. Koren G, Maltepe C, Navioz Y, Wolpin J. Recall bias of the symptoms of nausea and vomiting of pregnancy. *Am J Obstet Gynecol* 2004; **190**: 485–8.
106. Sherman JJ, LeResche L. Does experimental pain response vary across the menstrual cycle? A methodological review. *Am J Physiol Regul Integr Comp Physiol* 2006; **291**: R245–56.
107. Lagiou P, Tamimi R, Mucci LA, Trichopoulos D, Adami HO, Hsieh CC. Nausea and vomiting in pregnancy in relation to prolactin, estrogens, and progesterone: a prospective study. *Obstet Gynecol* 2003; **101**: 639–44.
108. Fujii Y. Postoperative nausea and vomiting and their sex differences. *Masui* 2009; **58**: 59–66.
109. Brandes JM. First-trimester nausea and vomiting as related to outcome of pregnancy. *Obstet Gynecol* 1967; **30**: 427–31.
110. Klebanoff MA, Koslowe PA, Kaslow R, Rhoads GG. Epidemiology of vomiting in early pregnancy. *Obstet Gynecol* 1985; **66**: 612–6.